Radient Pharmaceuticals Corp  

(Public, OTCMKTS:RXPC)   Watch this stock  
Find more results for AMEX:RPC
Delayed:   11:41AM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.00
Open     -
Vol / Avg. 0.00/5.76M
Mkt cap 134,794.00
P/E     -
Div/yield     -
EPS -10.87
Shares 1.35B
Beta     -
Inst. own 0%

Key stats and ratios

Q4 (Dec '11) 2011
Net profit margin -83592.69% -27486.69%
Operating margin -81710.24% -21313.15%
EBITD margin - -3166.74%
Return on average assets -17753.44% -8478.41%
Return on average equity - -
Employees 11 -
CDP Score - -


Suite 100, 2492 Walnut Avenue
TUSTIN, CA 92780
United States - Map
+1-714-5054460 (Phone)
+1-714-5054464 (Fax)

Website links


Radient Pharmaceuticals Corporation focuses on the discovery, development and commercialization of diagnostic tests that help physicians answer clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or recurrence. The Company is engaged in the development, manufacturing and delivery of products focused in one area, In Vitro Diagnostic Tests for the screening, monitoring and detection of more than 14 different types of cancer. The Company has two subsidiaries: AMDL Diagnostics Inc. and Jade Pharmaceuticals Inc. The Company�s Onko-Sure in vitro diagnostic test enables physicians and their patients to monitor and/or detect solid tumor cancers. The Company�s combination immunogene therapy (CIT) seeks to build the body�s immune system and destroy cancer cells. In December 2010, the Company in partnership with Jaiva Technologies, announced the formation of NuVax Therapeutics, Inc.